A Platform Study in Non-Small Cell Lung Cancer (NSCLC)

NCT06996782 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

152

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced or Metastatic Non-small Cell Lung Cancer

Interventions

DRUG: Rilvegostomig
DRUG: Cisplatin
DRUG: Carboplatin
DRUG: Pemetrexed
DRUG: Paclitaxel
DRUG: Nab-paclitaxel
DRUG: Ramucirumab

Sponsor

AstraZeneca